Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotechnology company MDRNA has acquired intellectual property related to non-nucleotide chemistry technology from RiboTask, a Danish company engaged in the development and synthesis of novel RNA chemistries.
Subscribe to our email newsletter
The technology will permit MDRNA to stabilize and provide drug-like properties to RISC and Dicer length small interfering RNAs (siRNAs) in a novel and proprietary manner. Terms of the agreement were not disclosed.
MDRNA has previously demonstrated that unlocked nucleic acid (UNA) has the potential to improve siRNA therapeutics by increasing stability and reducing sense- and antisense-mediated off-target effects while retaining potency.
Suzy Lena Wengel, co-founder and CEO of RiboTask, said: “While RiboTask is looking forward to commercializing the diagnostic and reagents applications of UNA, we are glad that this technology is in the hands of MDRNA whose scientific expertise and capabilities are necessary to bring UNA-siRNAi therapeutics to patients with significant unmet medical needs.”